Complement inhibitors and FcRn antagonists for myasthenia gravis

In this episode, James F. Howard, Jr., MD, FAAN, University of North Carolina School of Medicine, Chapel Hill, NC, discusses the results from the open-label extensions of the CHAMPION MG trial (NCT03920293) of ravulizumab and of the ADAPT trial (NCT03770403) that served as a basis for the FDA approval of efgartigimod. The current and future role of complement inhibitor therapy and the knowledge gaps that need to be addressed to optimize the management of myasthenia gravis are also discussed.